Arecur® is an innovative development of an international group of researchers who worked on methods of antirelapse immunocorrection in scientific and clinical centers of the USA, Mexico, Germany, Switzerland, Ukraine, Turkey, and Slovenia. Immunocorrection with the use of peptides is the most modern field of medicine, which has been intensively developing all over the world during the last 10 years. In 2020, certain groups of peptide medicine were approved by the FDA for clinical use. The International Institute of Biotherapy receives a peptide substance produced according to GMP standards and produces the medicine with the support of the leading laboratory of personalized medicine "Chemotheka".